| Medtronic-backed study falls short, reports say | Posted on 03/04/2008 in Medical Company Product News A study supported by Medtronic has failed in its attempt to establish that the use of cardiac-resynchronisation therapy (CRT) devices to coordinate beating in patients with erratic heartbeats prevents the condition of mild heart failure patients from getting worse, it has been claimed.
The main endpoint of the company's Reverse clinical study was not statistically significant, with the condition of 16 per cent of the patients fitted with the device worsening compared to 21 per cent for whom the device was left off, the Wall Street Journal said.
It added that the company would like to expand US sales of the product by expanding its scope to reach a relatively healthier patient base.
Despite this setback, the firm did claim to take some positives from the results of the Reverse trial.
Dr Cecilia Linde of Karolinska University Hospital, Stockholm, Sweden, said: "I believe this data indicates that in this study, CRT in combination with optimal medical therapy improved left ventricular function in this population of heart failure patients,?
She added that, furthermore, the use of CRT in mildly symptomatic patients was found to delay the time to first heart failure hospitalisation when measured over the 12-month follow-up period.
Last month, Medtronic announced the sale of its millionth continuous glucose monitoring product.
Other news stories from 03/04/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
